Nanomedicine for Cancer.

Abstract

Over the past decades, oncology has occupied the lion’s share of all nanomedical applications [1-3]. In 2020, up to 65% of the clinical trials involving nanomaterials were attending to cancer therapeutics and diagnostics [4]. The focus of most trials is not limited to enhancing the efficacy of available therapeutics or the accuracy and precision of existing diagnostic tools but rather directed to improving the quality of life of cancer patients. Indeed, one approach to overcoming drug resistance can be achieved via modulating the pharmacological characteristics of these therapies [4, 5]. This, in turn, permits their passive and selective delivery to the targeted tumorigenic sites. Furthermore, the use of biocompatible drug delivery systems embracing cancer-specific antibodies facilitates the active delivery of these therapeutics to cancer cells [6].